Full Description
This book provides an overview of the latest advances in head and neck cancer using a multidisciplinary approach. Commencing with a discussion of epidemiological and diagnostic aspects, including the role of vaccination and key pathological features, the book then follows by examining the role of oncogenomics, proteomics, next generation sequencing and homologous recombination function in predicting outcomes. The topics are presented by epidemiologists, pathologists and basic scientists with further contributions from medical oncologists, head and neck cancer surgical specialists (ORL /HNS), and radiation oncologists in chapters that discuss therapeutic approaches for oral, oropharyngeal and thyroid cancer. Special topics such as the development of novel staging classifications, optimal larynx preservation approaches for laryngeal and hypopharyngeal cancer, surgical reconstruction, new surgical approaches in oropharynx cancer, potential for treatment de-escalation, systemic therapyin nasopharyngeal cancer and salivary gland tumors and treatment approaches for tumors of unknown primary site are discussed in detail. Finally, the role of immunotherapy in the field is highlighted.
The chapters are based on the latest data presented at the 6th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field. They are written by many of the most internationally acclaimed authors in the field and are therefore an excellent source for all those interested or actively working in the field of head and neck cancer.
Contents
Part I. Epidemiology and diagnosis.- The role of vaccination in head and neck cancer prevention.- Cellular and molecular pathology in head and neck cancer.- Part II. Prediction of outcome.- Oncogenomics/proteomics of head and neck cancer.- Targeted next-generation sequencing in head and neck cancer.- Homologous recombination function as predictor of treatment response.- Part III. Oral cavity cancer.- Surgical management of oral cavity cancer.- Reconstruction in oral cavity cancer: when and how.- Induction chemotherapy: does it have a place in oral cavity cancer?.- Are there alternative local treatments in oral cavity cancer?.- Part IV. Oropharynx cancer.- HPV assessment in oropharynx cancer: what is the gold standard?.- A new staging system for oropharynx cancer and why?.- Should we de-escalate the treatment in HPV-positive oropharynx cancer?.- Is there a new role for surgery in oropharynx cancer?.- Can we expect less toxicity with newer forms of radiation?.- Part V. Miscellaneous topics.- What is the optimal larynx preservation approach and who are the candidates?.- Is the approach to patients with unknown primary tumors any different in 2017?.- Cytotoxic chemotherapy and targeted therapy in nasopharynx cancer.- Are there alternative chemotherapy regimens for EXTREME in recurrent/metastatic SCCHN.- New data on systemic therapy of salivary gland tumors.- Treatment of elderly patients with head and neck cancer.- Part VI. Thyroid cancer.- World-wide thyroid cancer epidemics: what is going on?.- The surgical approach to thyroid cancer in 2017.- Part VII. Keynote address.- Immunology and immunotherapy in head and neck cancer.-
